Patient Controlled, Off-label Use of Continuous Glucose Monitoring: Real-World Medical Costs and Effects of Patient Controlled Sensor Augmented Pump Therapy in Adult Patients Type 1 Diabetes

BACKGROUND: Continuous glucose monitoring (CGM) has shown promise to reduce glycated hemoglobin (HbA1c) levels, but its cost-effectiveness is seen as uncertain by reimbursement agencies. The aim of this study was to explore the impact of real-world, off-label, patient controlled CGM use in combinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidefjäll, Patrik, Berg, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Special Section: Impact of Quality Improvement on Improving Diabetes Management: Improving Glycemic Control
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111228/
https://www.ncbi.nlm.nih.gov/pubmed/32517514
http://dx.doi.org/10.1177/1932296820920909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111228/
https://www.ncbi.nlm.nih.gov/pubmed/32517514
http://dx.doi.org/10.1177/1932296820920909

Ejemplares similares